A mixed methods analysis of experiences and expectations among early‐career medical oncologists in Australia
WK Wong(UNSW Sydney), Zarnie Lwin(The University of Queensland), David Sibbritt(University of Technology Sydney), Christos S. Karapetis(Clínica Alemana), Deme Karikios(The University of Sydney), Alex Broom(The University of Sydney), Rosemary Harrup(University of Tasmania), Kay Francis(Medical Oncology Group of Australia), Emma Kirby(UNSW Sydney)
Cited by 7
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537